Basciani Mario, Di Rienzo Filomena, Bizzarrini Massimo, Zanchi Malvina, Copetti Massimiliano, Intiso Domenico
Unit of Neuro-rehabilitation, Hospital Scientific Institute "Casa Sollievo Della Sofferenza", Viale dei Cappuccini, 71013, San Giovanni Rotondo (FG), Italy.
Arch Dermatol Res. 2014 Jul;306(5):497-503. doi: 10.1007/s00403-014-1449-7. Epub 2014 Feb 14.
Primary palmar hyperhidrosis is a distressing and disabling condition that can produce social, psychological and occupational problems. Although the use of botulinum toxin type A (BoNT-A) has been reported as an efficacious and safe intervention to improve palmar hyperhidrosis, only one study concerned botulinum toxin type B (BoNT-B) in this disorder. The aim of study was to evaluate the efficacy and safety of BoNT-B in treating primary palmar hyperhidrosis. Participants were injected with 5,000 IU of BoNT-B in each palm. Visual analogue test (VAS) to evaluate the intensity of decrease in sweat production, Minor's iodine starch test and measurement of paper towels' weight were used to ascertain palmar sweating at baseline, 4, 12 and 24 weeks after BoNT-B injections by a blind examiner. Thirty-two subjects (12 males, 20 females, mean age 31 ± 11) were enrolled. Significant reduction of palmar sweating was detected after BoNT-B injection: 2.9 ± 1.4, 0.3 ± 0.4, 0.9 ± 0.8, and 2.1 ± 1.5 g (p < 0.001) of paper towels' weight for the right palm at baseline, 4, 12 and 24 weeks; and 2.8 ± 1.7, 0.5 ± 0.6, 0.8 ± 0.7, and 1.8 ± 1.25 g (p < 0.001) at same time, respectively for the left palm. Significant reduction of mean VAS values were also detected after BoNT-B injections: 8.6 ± 1.1, 0.6 ± 0.8, 3.5 ± 2.5, and 7.1 ± 2.4 (p < 0.0001) at baseline, 4, 12 and 24 weeks, respectively. Mild side effects consisting in local pain and hand weakness were observed in 4 (12.5%) subjects. The findings indicated that the use of 5,000 IU BoNT-B injection in each palm was safe and significantly improved the severity of palmar hyperhidrosis.
原发性手掌多汗症是一种令人苦恼且致残的病症,会引发社交、心理和职业方面的问题。尽管已有报道称使用A型肉毒毒素(BoNT-A)是改善手掌多汗症的一种有效且安全的干预措施,但仅有一项研究涉及肉毒毒素B(BoNT-B)在该病症中的应用。本研究的目的是评估BoNT-B治疗原发性手掌多汗症的疗效和安全性。给参与者每只手掌注射5000国际单位的BoNT-B。由一位盲法检查者通过视觉模拟测试(VAS)评估汗液分泌减少的强度,使用Minor氏碘淀粉试验和测量纸巾重量来确定在注射BoNT-B前、注射后4周、12周和24周时的手掌出汗情况。共招募了32名受试者(12名男性,20名女性,平均年龄31±11岁)。注射BoNT-B后检测到手掌出汗显著减少:右手掌在基线、4周、12周和24周时纸巾重量分别为2.9±1.4、0.3±0.4、0.9±0.8和2.1±1.5克(p<0.001);左手掌在相同时间分别为2.8±1.7、0.5±0.6、0.8±0.7和1.8±1.25克(p<0.001)。注射BoNT-B后平均VAS值也显著降低:在基线、4周、12周和24周时分别为8.6±1.1、0.6±0.8、3.5±2.5和7.1±2.4(p<0.0001)。4名(12.5%)受试者出现了包括局部疼痛和手部无力在内的轻度副作用。研究结果表明,每只手掌注射5000国际单位BoNT-B是安全的,且能显著改善手掌多汗症的严重程度。